Endeavor BioMedicines reveals encouraging results for ENV-101 in Phase 2a idiopathic pulmonary fibrosis trial
Endeavor BioMedicines, a clinical-stage biotechnology company, has announced encouraging results from their completed Phase 2a clinical trial of ENV-101, showing improved lung function and a ... Read More